TickerFacts.

Compare

Nature's Sunshine Products Inc vs Travere Therapeutics, Inc. vs BridgeBio Pharma, Inc. vs Zai Lab Ltd

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearNature's Sunshine Products Inc
NATR		Travere Therapeutics, Inc.
TVTX		BridgeBio Pharma, Inc.
BBIO		Zai Lab Ltd
ZLAB
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$480.14M$490.73M$502.08M$457.18M
Revenue growth (YoY)+5.7%+110.5%+126.3%+15.0%
Gross margin72.4%n/an/a58.3% (computed)
Operating margin5.2%-12.8%-104.2%-50.2%
Net margin4.3%-5.2%-146.0%-38.4%
Net income$20.45M-$25.55M-$732.94M-$175.54M
EPS (Diluted)$1.06-$0.29-$3.78-$0.16
Operating cash flow$35.32M$37.78M-$445.91M-$150.79M
Free cash flow$28.84Mn/a-$447.01M-$158.89M
Cash & equivalents$93.89M$93.03M$570.12M$679.57M
Total assets$261.15M$605.19M$936.02M$1.17B
Total liabilities$99.59M$490.36M$3.01B$456.88M
Shareholders' equity$161.55M$114.83M-$2.09B$715.50M
Return on year-end equity12.7%-22.2%n/a-24.5%
Shares outstanding17.51M90.92M194.77M1.11B

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearNature's Sunshine Products IncTravere Therapeutics, Inc.BridgeBio Pharma, Inc.Zai Lab Ltd
Latest$480.14M
Ended 2025-12-31		$490.73M
Ended 2025-12-31		$502.08M
Ended 2025-12-31		$457.18M
Ended 2025-12-31
1 year earlier$454.36M
Ended 2024-12-31		$233.18M
Ended 2024-12-31		$221.90M
Ended 2024-12-31		$397.61M
Ended 2024-12-31
2 years earlier$445.32M
Ended 2023-12-31		$145.24M
Ended 2023-12-31		$9.30M
Ended 2023-12-31		$266.72M
Ended 2023-12-31
3 years earlier$421.91M
Ended 2022-12-31		$109.46M
Ended 2022-12-31		$77.65M
Ended 2022-12-31		$212.67M
Ended 2022-12-31
4 years earlier$444.08M
Ended 2021-12-31		$131.84M
Ended 2021-12-31		$69.72M
Ended 2021-12-31		$144.10M
Ended 2021-12-31